Evidence map›Paper›PMID 37591714›Full record

ReviewTrends in immunology2023

Circulating IRF8-expressing CD123

Kai Ling Liang, Elisa Laurenti, Tom Taghon

Open access · greenAbstract readReview
In one paragraph

Review in Trends in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Frontiers in immunology · 2025
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Kai Ling LiangDepartment of Diagnostic Sciences, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent, Ghent, Belgium.
Elisa LaurentiDepartment of Haematology, University of Cambridge, Cambridge, UK; Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.
Tom TaghonDepartment of Diagnostic Sciences, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent, Ghent, Belgium. Electronic address: Tom.Taghon@UGent.be.
Ghent University · BEWellcome/MRC Cambridge Stem Cell Institute · GB

Funding

Biotechnology and Biological Sciences Research Council BB/P002293/1Medical Research Council MC_PC_17230Wellcome Trust 107630Wellcome Trust 107630/Z/15/ZWellcome Trust 203151/Z/16/Z
6 · The paper itself

Abstract

Lymphopoiesis is the process in which B and T cells, and innate lymphoid cells (ILCs) develop from hematopoietic progenitors that exhibit early lymphoid priming. The branching points where lymphoid-primed human progenitors are further specified to B/T/ILC differentiation trajectories remain unclear. Here, we discuss the emerging role of interferon regulatory factor (IRF)8 as a key factor to bridge human lymphoid and dendritic cell (DC) differentiation, and the current evidence for the existence of circulating and tissue-resident CD123

Indexed as

Immunity, InnateInterleukin-3 Receptor alpha SubunitHematopoiesisHumansInterferon Regulatory Factor-8Interferon Regulatory FactorsLymphocytesInterferon Regulatory Factor-8Interferon Regulatory FactorsInterleukin-3 Receptor alpha Subunithematopoiesishematopoietic tissueshumanIRF8lineage cell fatelymphoid progenitor cells

Identifiers

PMID37591714
PMCPMC7614993
OpenAlexW4385841161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.